Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users

American Journal of Public Health

Volumn 99, Issue 6, 2009, Pages 1049-1052

  Wiessing, Lucas ^a   Likatavičius, Giedrius ^b   Klempová, Danica ^b   Hedrich, Dagmar ^b   Nardone, Anthony ^b   Griffiths, Paul ^b  

^a EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE; NARCOTIC ANALGESIC AGENT;

ARTICLE; AUSTRALIA; CANADA; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTRAVENOUS DRUG ABUSE; PREVALENCE; RUSSIAN FEDERATION; UKRAINE; UNITED STATES; COMPARATIVE STUDY; COUNSELING; CULTURAL FACTOR; DEVELOPED COUNTRY; DRUG USE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; PREVENTIVE HEALTH SERVICE; SUBSTANCE ABUSE; VIROLOGY;

ANALGESICS, OPIOID; COUNSELING; CROSS-CULTURAL COMPARISON; DEVELOPED COUNTRIES; DRUG USERS; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; NEEDLE-EXCHANGE PROGRAMS; PREVENTIVE HEALTH SERVICES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 67049119256     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2008.141846     Document Type: Article

References (36)

1. Des Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet. 1996;348:987-991.
2. Ball AL, Rana S, Dehne KL. HIV prevention among injecting drug users: responses in developing and transitional countries. Public Health Rep.1998;113(suppl 1):170-181.
3. Sarang A, Stuikyte R, Bykov R. Implementation of harm reduction in Central and Eastern Europe and Central Asia. Int J Drug Policy. 2007;18:129-135.
4. Hammett TM, Wu Z, Duc TT, et al. "Social evils" and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam. Addiction. 2008;103(1):137-145.
5. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, PrinsM. Full participation in harm reduction programmes is associated with decreased risk for human immunode-ficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007;102:1454-1462.
6. Committee on the Prevention of HIV Infection Among Injecting Drug Users in High-Risk Countries. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC: National Academy of Sciences; 2007. Available at: http://www.nap.edu/catalog/ 11731.html. Accessed April 5, 2009.
7. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the Effectiveness of Harm Reduction Interventions in Preventing Hepatitis C Transmission Among Injecting Drug Users: A Review of Reviews. Executive Summary. Glasgow, Scotland: Health Protection Scotland; 2008. Available at: http://www.hepcscotland.co.uk/pdfs/p-Evidence-for-the- Effectivenessof-Harm-Reduction-review-EXECUTIVE%20SUMMARY-2008-05.pdf. Accessed April 5, 2009.
8. Commission on Narcotic Drugs, United Nations Office on Drugs and Crime, United Nations Economic and Social Council. Responding to the prevalence of HIV/AIDS and other blood-borne diseases among drug users. Report presented at: Commission on Narcotic Drugs 51st Session; March 10-14, 2008; Vienna, Austria. Available at: http://daccessdds.un.org/doc/UNDOC/GEN/V08/501/78/PDF/V0850178. pdf?OpenElement. Accessed March 7, 2008.
9. Wiessing LG, Denis B, Guttormsson U, et al. Estimating coverage of harm-reduction measures for injection drug users in Europe. Paper presented at: Global Research Network on HIV Prevention in Drug-Using Populations Third Annual Meeting; July 5-7, 2000; Durban, South Africa. Available at: http://www.emcdda.europa.eu/?fuseaction=public.AttachmentDownload&nNodeID= 1527. Accessed February 15, 2008.
10. Mathers B, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733-1745.
11. HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia Annual Surveillance Report 2007. Darlinghurst, Australia: National Centre in HIV Epidemiology and Clinical Research; 2007. Available at: http://www.nchecr.unsw.edu.au/NCHECRweb.nsf/resources/SurvRep07/$file/ ASR2007.PDF. Accessed February 15, 2008.
12. HIV/AIDS Surveillance in Europe. Mid-Year Report 2007. Saint-Maurice, France: EuroHIV; 2007. No. 76. Available at: http://www.eurohiv. org/reports/report-76/pdf/report-eurohiv-76.pdf. Accessed February 15, 2008.
13. HIV and AIDS in Canada: Surveillance Report to December 31, 2006. Ottawa, Ontario: Public Health Agency of Canada; 2007. Available at: http://www.phac-aspc.gc.ca/aids-sida/publication/survreport/pdf/survrep1206.pdf. Accessed February 15, 2008.
14. HIV/AIDS Surveillance Report, 2005. Atlanta, GA: Centers for Disease Control and Prevention; 2007. Available at: http://www.cdc.gov/hiv/ topics/surveillance/resources/reports/2005report/pdf/2005 SurveillanceReport. pdf. Accessed February 15, 2008.
15. 2007 Annual Report on the State of the Drugs Problem in the European Union. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction; 2007. Available at: http://www.emcdda.europa.eu/html.cfm/ index44682EN.html. Accessed February 15, 2008.
16. Wiessing L, Nardone A. Ongoing HIV and viral hepatitis infections in IDUs across the EU, 2001-2005. Euro Surveill. 2006;11(47). Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=3084.
17. Hedrich D, Pirona A, Wiessing L. From margin to mainstream: the evolution of harm reduction responses to problem drug use in Europe. Drugs Educ Prev Policy. 2008;15(6):503-517.
18. Sendziuk P. Harm reduction and HIV-prevention among injecting drug users in Australia: an international comparison. Can Bull Med Hist.2007;24:113- 129.
19. Burrows D. Injecting equipment provision in Australia: the state of play. Subst Use Misuse. 1998;33:1113-1127.
20. Hankins CA. Syringe exchange in Canada: good but not enough to stem the HIV tide. Subst Use Misuse. 1998;33(5):1129-1146.
21. Loxley W. Doing the possible: harm reduction, injecting drug use and blood borne viral infections in Australia. Int J Drug Policy. 2000;11:407-416.
22. Razali K, Thein HH, Bell J, et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend. 2007;91:228-235.
23. Bruneau J, Schechter MT. The politics of needles and AIDS. New York Times. April 9, 1998. Available at: http://www.mapinc.org/newscsdp/v98/n258/ a05.html. Accessed April 15, 2009.
24. Popova S, Rehm J, Fischer B. An overview of illegal opioid use and health services utilization in Canada. Public Health. 2006;120:320-328.
25. Barnett PG, Hui SS. The cost-effectiveness of methadone maintenance. Mt Sinai J Med.2000;67:365-374.
26. US FDA marketing approval for Reckitt Benckiser's Subutex & Suboxone [press release]. Slough, England: Reckitt Benckiser; October 9, 2002. Available at: http://www.reckittbenckiser.com/site/RKBR/Templates/MediaLatestNewsItem. aspx?pageid=144. Accessed December 2, 2008.
27. Response to ASAM's Public Policy Statement on Of-fice-Based Opioid Agonist Treatment. New York, NY: American Association for the Treatment of Opioid Dependence; 2005. Available at: http://www.aatod.org/pdfs/ASAM-Policy- Comm-March-05-2.pdf. Accessed March 3, 2008.
28. Syringe exchange programs. Atlanta, GA: Centers for Disease Control and Prevention; December 2005. Available at: http://www.cdc.gov/idu/facts/aed-idu- syr.htm. Accessed February 15, 2008.
29. Access to sterile syringes. Atlanta, GA: Centers for Disease Control and Prevention; December 2005. Available at: http://www.cdc.gov/idu/facts/aed-idu- acc.htm. Accessed February 15, 2008.
30. Tempalski B, Cooper HL, Friedman SR, Des Jarlais DC, Brady J, Gostnell K. Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug. Int J Drug Policy. 2008;19(suppl 1):S47-S58.
31. Aceijas C, Hickman M, Donoghoe MC, Burrows D, Stuikyte R. Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia. Addiction. 2007;102:1244-1250.
32. Perriens J. A global perspective on scaling up harm reduction. Paper presented at: 2nd National Harm Reduction Conference of the World Health Organization; March 21-23, 2007; Kiev, Ukraine. Available at: http://www.who.int/hiv/idu/JPerriens-globalIDU.ppt. Accessed March 3, 2008.
33. Sarang A, Rhodes T, Platt L.Access to syringes in three Russian cities: implications for syringe distribution and coverage. Int J Drug Policy. 2008;19(suppl 1):S25-S36.
34. Bruce RD, Dvoryak S, Sylla L, Altice FL. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine-programme description and policy implications. Int J Drug Policy. 2007;18:326-328.
35. Pharmacy sales of sterile syringes. Atlanta, GA: Centers for Disease Control and Prevention; December 2005. Available at: http://www.cdc.gov/idu/ facts/aed-idu-phar.htm. Accessed February 15, 2008.
36. Transnational Institute. 2005 CND debate. UNGASS 10-Year Review Web site. Available at: http://www.ungassondrugs.org/index.php?option=com- content&;task=blogcategory&id=56&Itemid=102. Accessed September 21, 2008.